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Abstract
Dengue is the most important arboviral infection of humans. Thrombocytopenia is frequently observed in the course of
infection and haemorrhage may occur in severe disease. The degree of thrombocytopenia correlates with the severity of
infection, and may contribute to the risk of haemorrhage. As a result of this prophylactic platelet transfusions are sometimes
advocated for the prevention of haemorrhage. There is currently no evidence to support this practice, and platelet
transfusions are costly and sometimes harmful. We conducted a global survey to assess the different approaches to the use
of platelets in dengue. Respondents were all physicians involved with the treatment of patients with dengue. Respondents
were asked that their answers reflected what they would do if they were the treating physician. We received responses from
306 physicians from 20 different countries. The heterogeneity of the responses highlights the variation in clinical practice
and lack of an evidence base in this area and underscores the importance of prospective clinical trials to address this key
question in the clinical management of patients with dengue.
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Introduction
Dengue is globally the most important arboviral infection and
threatens an estimated 2.5 billion people worldwide [1]. Throm-
bocytopenia is almost universally observed in dengue infection [2].
This results from both reduced production and increased
destruction of platelets [3–5]. It is thought that severe thrombo-
cytopenia correlates with disease severity and may contribute to
the risk of developing haemorrhage [6,7]. The 2009 WHO dengue
guidelines do not advocate the use of prophylactic platelet
transfusions, whereas the 2011 regional WHO guidelines for
South East Asia suggest prophylactic platelets may be considered
in those with a platelet count less than 106109/L [8,9]. Some
dengue-endemic countries support the use of prophylactic platelet
transfusions to prevent haemorrhage in patients with thrombocy-
topenia, for example India (,106109/L), whereas others, such as
Brazil, do not [10,11]. However platelet transfusions are costly,
potentially dangerous and their use in dengue lacks an evidence
base [12–15].
Methods
We conducted a survey among physicians directly involved in
the care of dengue patients in order to determine how platelets are
used in the clinical management of dengue. The majority of
respondents were practicing physicians in dengue-endemic areas.
The exceptions to this were respondents from Africa, where
dengue is emerging, and the UK where the respondents were
infectious disease physicians who regularly see patients who have
recently travelled to dengue-endemic areas. A questionnaire
containing nine case histories and an additional question about
prophylactic platelet transfusion thresholds was emailed to
physicians with experience in managing dengue patients and
known to us. Respondents were specifically asked that their
www.plosntds.org 1 June 2012 | Volume 6 | Issue 6 | e1716
responses reflect what they would do if they were the treating
physician. Email recipients were invited to further disseminate the
questionnaire within their own clinical networks. The complete list
of questions is available as a supplementary file (Questionnaire S1).
The case histories were based on real clinical cases seen at the
Hospital for Tropical Diseases in Ho Chi Minh City, Vietnam.
Four case histories describe patients with clinically non-severe
dengue but varying levels of thrombocytopenia. Case 1 describes
an 18-year-old female with platelets of 236109/L and no bleeding.
Case 2 describes a 28-year-old male with platelets of 296109/L.
He had no bleeding but a past history of a perforated peptic ulcer.
Case 3 describes a 29-year-old female with a rapid fall in platelets
to 226109/L. She had no bleeding. Case 4 describes a 30-year-old
male with platelets of 36109/L and no bleeding. Five case
histories describe patients with different manifestations of severe
dengue associated with varying levels of thrombocytopenia. Case 5
describes a 19-year-old male with platelets of 186109/L. He had
dengue hepatitis but no bleeding. Case 6 describes a 20-year-old
female with platelets of 176109/L. She had suspected dengue
encephalitis but no bleeding. Case 7 describes a 24-year-old male
with platelets of 316109/L. He had hepatic failure thought to be
secondary to dengue but no bleeding. Case 8 describes a 23-year-
old female with platelets of 86109/L. She had shock, epistaxis and
vaginal bleeding. Case 9 describes a 23-year-old male with
platelets of 336109/L. He had shock and mucosal bleeding. The
final question aimed to determine thresholds at which a physician
would consider transfusing platelets as prophylaxis against
haemorrhage. Respondents were asked to select a single option.
Results
In total, 306 physicians from 20 different countries responded
within a specified time period. The responses from Asia were 52
from Indonesia, 7 from Bangladesh, 5 from the Philippines, 9 from
Singapore, 8 from Cambodia, 18 from Malaysia, 3 from Thailand,
20 from Vietnam and 12 from India. The responses from Latin
America and the Caribbean were 13 from Cuba, 10 from Brazil,
17 from Paraguay, 6 from Peru, 1 from Mexico, 1 from Bolivia, 1
from Martinique and 81 from Colombia. The responses from
Africa were 37 from Nigeria and 2 from South Africa. In addition
there were 3 responses from the UK.
Among the 4 case histories describing patients with clinically
non-severe dengue associated with varying levels of thrombocy-
topenia, 16–24% of respondents recommended platelet transfu-
sion at platelet concentrations of 22–296109/L., but approxi-
mately one-third of the respondents would transfuse platelets if the
count fell to 36109/L. (Table 1)
Among the 5 case histories describing patients with different
manifestations of severe dengue associated with varying levels of
thrombocytopenia, more respondents would transfuse platelets if
the patient was in shock and bleeding (case histories 8 and 9).
There were substantial differences in the responses from physicians
in Africa than those from Asia and America for all 9 cases
(Table 1).
The final question aimed to determine thresholds at which a
physician would consider transfusing platelets as prophylaxis
against haemorrhage. Respondents were asked to select a single
option. 31 (10%) respondents would consider a prophylactic
platelet transfusion if the platelet count was below 506109/L. 8
(2.6%) respondents would consider a prophylactic platelet
transfusion if the platelet count was below 406109. 10 (3.3%)
respondents would consider a prophylactic platelet transfusion if
the platelet count was below 306109. 17 (5.6%) respondents would
consider a prophylactic platelet transfusion if the platelet count
was below 206109. 46 (15%) respondents would consider a
prophylactic platelet transfusion if the platelet count was below
106109. 190 (62%) respondents would only consider transfusing
platelets in patients with signs of haemorrhage.
The responses categorised by global region are summarised in
Table 1.
Discussion
Our study has limitations. There is an element of selection bias
in the way the survey was conducted, as the physicians who
distributed the survey within their countries were known to have
an interest in dengue. The survey is subject to response bias
meaning that the answers may not accurately reflect clinical
practice in the respective countries. In addition, the country
representation is not balanced.
Despite these limitations the striking result of this survey is the
heterogeneity of approaches to the use of prophylactic platelet
transfusions in dengue. 112/306 respondents would consider
transfusing platelets prophylactically at various levels of thrombo-
cytopenia. When the responses are categorised by region (Table 1)
African respondents would advocate platelet transfusions more
frequently, perhaps reflecting more limited experience with
dengue and experience with other haemorrhagic fevers. The
choice to use prophylactic platelet transfusions may be influenced
by cost and availability of platelets, as well as individual experience
in managing dengue and other medical conditions that affect the
platelet count. There is considerable variability within countries
suggesting an individual’s practice may differ from recommenda-
tions in guidelines. For example 6/12 Indian respondents and 7/
10 Brazilian respondents would consider the use of prophylactic
platelets. The responses reflect wide variation in clinical practice
and are indicative of the paucity of clinical evidence to guide
practice in this area.
At present there is limited evidence to support the use of
prophylactic platelet transfusions in dengue despite their inclusion
in some national guidelines. As the global reach of dengue
continues to expand the need to conduct clinical trials to construct
Author Summary
A low platelet count is a common feature of dengue
infection. It is thought that the platelet count correlates
with the severity of the infection and may contribute to
the risk of developing haemorrhage, a well-recognised
complication of dengue. As a result of this platelet
transfusions are used in some settings to reduce the risk
of haemorrhage. There is currently no evidence to support
this practice, and platelet transfusions are costly and
sometimes harmful. We conducted a survey assessing the
use of platelets in dengue. Respondents were all physi-
cians involved with the treatment of patients with dengue.
Respondents were asked that their answers reflected what
they would do if they were the treating physician. We
received 306 responses from 20 different countries. The
striking feature of the survey responses was the hetero-
geneity of approaches to the use of platelets in dengue.
These findings highlight the variation in clinical practice
and lack of an evidence base in this area and underscore
the importance of conducting prospective clinical trials to
address this key question in dengue clinical management.
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an evidence base to guide the appropriate use of platelets in
dengue becomes ever more pressing.
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Table 1. Proportion of respondents choosing to transfuse platelets stratified by geographic region (n, (%)); BP = blood pressure;
HR =heart rate; HCT=haematocrit.
Clinical case
Asia
(n =134)
Africa
(n =39)
S. America
& Caribbean
(n=130) UK (n=3)
Total
(n =306)
Case 1 18-year-old female; platelets 236109/L; no haemorrhage; BP 120/80; HR 105; HCT 39% 12 (9) 38 (97.4) 8 (6.2) 0 (0) 58 (19)
Case 2 28-year-old male; platelets 296109/L; no haemorrhage; past history of perforated
gastric ulcer; BP 100/75; HR 92; HCT 42%3
20 (14.9) 39 (100) 13 (10) 0 (0) 72 (23.5)
Case 3 29-year-old female; rapid fall in platelets to 226109/L; no haemorrhage;
haemodynamically stable
12 (9) 30 (76.9) 6 (4.6) 0 (0) 48 (15.7)
Case 4 30-year-old male; platelets 36109/L; no haemorrhage; haemodynamically stable 57 (42.5) 37 (94.9) 23 (17.7) 3 (100) 120 (39.2)
Case 5 19-year-old male; platelets 186109/L; dengue hepatitis; no haemorrhage; BP 90/60;
HR 120; HCT 47%
11 (8.2) 36 (92.3) 7 (5.4) 2 (66.7) 56 (18.3)
Case 6 20-year-old female; platelets 176109/L; dengue encephalitis; no haemorrhage;
BP 100/70; HR 100; HCT 40%
25 (18.7) 39 (100) 19 (14.6) 1 (33.3) 84 (27.5)
Case 7 24-year-old male; platelets 316109/L; hepatic failure secondary to dengue; no
haemorrhage; BP 125/70; HR 110; HCT 42%
5 (3.7) 39 (100) 9 (6.9) 0 (0) 53 (17.3)
Case 8 23-year-old female; platelets 86109/L; shock, epistaxis and vaginal bleeding; BP 75/50;
HR 110; HCT 42%
86 (64.2) 39 (100) 43 (33.1) 3 (100) 171 (55.9)
Case 9 23-year-old male; platelets 336109/L; shock and mucosal bleeding; BP 70/50; HR 120;
HCT 46%
57 (42.5) 39 (100) 26 (20) 1 (33.3) 123 (40.2)
Prophylactic platelet transfusion threshold:
,506109/L 8 (6) 23 (59) 0 (0) 0 (0) 31 (10.1)
,406109/L 1 (0.7) 7 (17.9) 0 (0) 0 (0) 8 (2.6)
,306109/L 1 (0.7) 7 (17.9) 2 (1.5) 0 (0) 10 (3.3)
,206109/L 12 (9) 1 (2.6) 2 (1.5) 2 (66.7) 17 (5.6)
,106109/L 33 (24.6) 0 (0) 12 (9.2) 1 (33.3) 46 (15)
Not in absence of bleeding 75 (56) 1 (2.6) 39 (30) 0 (0) 190 (62.1)
doi:10.1371/journal.pntd.0001716.t001
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